<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639726</url>
  </required_header>
  <id_info>
    <org_study_id>19.14.CLI</org_study_id>
    <nct_id>NCT04639726</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Pre-Meal Whey Protein Microgels Administration on Post-Prandial Glycemic Response.</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Single-Center, Crossover Study to Evaluate the Effects of Pre-Meal Whey Protein Microgels Administration on Post-Prandial Glycemic Response in Patients With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a mechanistic, randomized, investigator-blinded, placebo-controlled, single-center,&#xD;
      crossover study designed to evaluate the effects of premeal administration of whey protein&#xD;
      microgels compared to placebo on postprandial glycemia in patients with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Actual">October 26, 2020</completion_date>
  <primary_completion_date type="Actual">October 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-prandial glycemic excursion.</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Incremental area under the curve post-prandial glycemic excursion (iAUC 0-3 hours)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2h post-prandial glucose</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Incremental area under the curve 2hours post-prandial glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total glucose</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Total glucose AUC (tAUC 0-3hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Plasma glucose iCmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Plasma glucose Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Plasma glucose AUC (iAUC 0-4hours, tAUC 0-4hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Serum insulin (iAUC 0-3hours, iCmax, Tmax, tAUC 0-3hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucagon</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Plasma glucagon (iAUC 0-3hours, iCmax, Tmax, tAUC 0-3hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucagon-like Peptide-1</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Plasma GLP-1 (iAUC 0-2hours, iCmax, Tmax, tAUC 0-2hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Gastric Inhibitory Polypeptide</measure>
    <time_frame>-15, 0, 30, 60, 90, and 120 minutes.</time_frame>
    <description>Plasma GIP (iAUC 0-2hours, iCmax, Tmax, tAUC 0-2hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma ghrelin</measure>
    <time_frame>-15, 0, 30, 60, 90, and 120 minutes.</time_frame>
    <description>Plasma ghrelin (iAUC 0-2hours, iCmax, Tmax, tAUC 0-2hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma cholecystokinin</measure>
    <time_frame>-15, 0, 30, 60, 90, and 120 minutes.</time_frame>
    <description>Plasma cholecystokinin (CCK) (iAUC 0-2hours, iCmax, Tmax, tAUC 0-2hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma peptide</measure>
    <time_frame>-15, 0, 30, 60, 90, and 120 minutes.</time_frame>
    <description>Plasma peptide-YY (PYY) (iAUC 0-2hours, iCmax, Tmax, tAUC 0-2hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triglycerides</measure>
    <time_frame>-15, 0, 30, 60, 90, and 120 minutes.</time_frame>
    <description>Serum triglycerides (iAUC 0-2hours, iCmax, Tmax, tAUC 0-2hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying</measure>
    <time_frame>-15, 0, 15, 30, 45, 60, 90, 120, 180, and 240 minutes.</time_frame>
    <description>Gastric emptying (AUC 0-4hours, Cmax and Tmax for acetaminophen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-cell function I</measure>
    <time_frame>-15, 0, 30, 60, 90, and 120 minutes.</time_frame>
    <description>Beta-cell function I: AUC insulin 0-3hours: AUC glucose 0-3hours ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-cell function II</measure>
    <time_frame>-15, 0, 30, 60, 90, and 120 minutes.</time_frame>
    <description>Beta-cell function II: Insulinogenic index (IGI): [insulin (30-0 minutes) (μU/mL)/glucose (30-0 minutes) (mg/dL)]</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>0, 15, 30, 45, 60, 90, 120, 150, 180, and 240 minutes</time_frame>
    <description>Plasma glucose at individual timepoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum insulin</measure>
    <time_frame>0, 15, 30, 45, 60, 90, 120, 150, 180, and 240 minutes</time_frame>
    <description>Serum insulin at individual timepoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma glucagon</measure>
    <time_frame>0, 15, 30, 45, 60, 90, 120, 150, 180, and 240 minutes)</time_frame>
    <description>Plasma glucagon at individual timepoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Plasma glucose (iAUC 0-2hours, iAUC 0-1hour, tAUC 0-2hours, tAUC 0-1hour)</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum insulin</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Serum insulin (iAUC 0-4hours, tAUC 0-4hours, iAUC 0-2hours, tAUC 0-2hours, iAUC 0-1hour, tAUC 0-1hour)</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma glucagon</measure>
    <time_frame>-30, -15, 0, 15, 30, 45, 60, 120,150, 180, and 240 minutes.</time_frame>
    <description>Plasma glucagon (iAUC 0-4hours, tAUC 0-4hours, iAUC 0-2hours, tAUC 0-2hours, iAUC 0-1hour, tAUC 0-1hour)</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma GLP-1</measure>
    <time_frame>-15, 0, 30, 60, 90, 120 minutes.</time_frame>
    <description>Plasma GLP-1 (iAUC 0-1hour, tAUC 0-1hour)</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma GIP</measure>
    <time_frame>-15, 0, 30, 60, 90, 120 minutes.</time_frame>
    <description>Plasma GIP (iAUC 0-1hour, tAUC 0-1hour)</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum triglycerides</measure>
    <time_frame>-15, 0, 30, 60, 90, 120 minutes</time_frame>
    <description>Serum triglycerides (iAUC 0-1hour, tAUC 0-1hour)</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma ghrelin</measure>
    <time_frame>-15, 0, 30, 60, 90, 120 minutes</time_frame>
    <description>Plasma ghrelin (iAUC 0-1hour, tAUC 0-1hour)</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma cholecystokinin</measure>
    <time_frame>-15, 0, 30, 60, 90, 120 minutes</time_frame>
    <description>Plasma cholecystokinin (CCK) (iAUC 0-1hour, tAUC 0-1hour)</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma peptide</measure>
    <time_frame>-15, 0, 30, 60, 90, 120 minutes.</time_frame>
    <description>Plasma peptide-YY (PYY) (iAUC 0-1hour, tAUC 0-1hour)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Dietary Supplement</condition>
  <arm_group>
    <arm_group_label>Whey Protein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whey Protein Micro Gel</intervention_name>
    <description>The test product is whey protein microgels 10g, reconstituted in 125ml water.</description>
    <arm_group_label>Whey Protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Water without Whey Protein.</intervention_name>
    <description>A matching placebo (125ml of water without whey protein) will be used as control.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to sign written informed consent prior to study entry.&#xD;
&#xD;
          -  Male or female, &gt;18 years of age.&#xD;
&#xD;
          -  Established diagnosis of type 2 diabetes (documented by either HbA1c 6.5 - 10.0% or a&#xD;
             history of type 2 diabetes diagnosis).&#xD;
&#xD;
          -  Treatment naïve or on active therapy with metformin at a daily dose of 1000-3000mg at&#xD;
             screening. Dose of metformin must have been stable for at least 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Patients must have a hematocrit value greater than or equal to 34.0% for females and&#xD;
             40% for males.&#xD;
&#xD;
          -  Patients must have a hemoglobin value greater than or equal to 11.0 g/dL for females&#xD;
             and 13.5 g/dL for males.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fasting plasma glucose &gt;220mg/dl at screening.&#xD;
&#xD;
          -  Impaired kidney function, epidermal growth factor receptor of &lt;60mL/min/1.73m2 at&#xD;
             screening.&#xD;
&#xD;
          -  BMI &gt;40kg/m2.&#xD;
&#xD;
          -  Elevated liver transaminase &gt; 3 upper limit of normal at screening.&#xD;
&#xD;
          -  Ongoing or recent (i.e. &lt; 3month) treatment with any oral or injectable&#xD;
             glucose-lowering drug other than metformin.&#xD;
&#xD;
          -  Ongoing or recent (i.e. &lt; 3month) injectable insulin therapy.&#xD;
&#xD;
          -  Ongoing or recent (i.e. &lt; 3 month) weight loss interventions (e.g. dietary weight loss&#xD;
             programs) or any history of bariatric surgery or any documented weight loss &gt;5% within&#xD;
             previous 6 months.&#xD;
&#xD;
          -  Ongoing or recent (i.e. &lt; 3 month) treatment with anorectic drugs, systemic steroids,&#xD;
             medications known to affect gastric motility, or any condition known to affect&#xD;
             gastro-intestinal integrity and food absorption.&#xD;
&#xD;
          -  Major medical/surgical event requiring hospitalization in the last 3 months.&#xD;
&#xD;
          -  Known allergy and intolerance to product components or acetaminophen.&#xD;
&#xD;
          -  Alcohol intake higher than 2 servings per day. A serving is 0.4dl of strong alcohols,&#xD;
             1dl of red or white wine, or 3dl of beer.&#xD;
&#xD;
          -  Are unable to comply with protocol procedures in the opinion of the investigator.&#xD;
&#xD;
          -  Have a hierarchical link with the research team members.&#xD;
&#xD;
          -  Positive pregnancy test at screening.&#xD;
&#xD;
          -  Patients who have been dosed in another clinical trial with any investigational&#xD;
             drug/new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to&#xD;
             screening, or patients currently participating in any investigational trial.&#xD;
&#xD;
          -  Donation of blood or significant amount of blood loss within 8 weeks prior to&#xD;
             screening. Patients must also agree to not donate blood within 8 weeks after their&#xD;
             last visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel M Neutel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orange County Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

